Nervous System & Special Senses

Lewy body dementia: diagnosis and management considerations

Clinical Overview and When to Suspect Lewy Body Dementia

— Fluctuating cognition with pronounced variations in attention/alertness

— Recurrent, well-formed visual hallucinations (often animals, children, small people)

— REM sleep behavior disorder (RBD) — acting out dreams, often preceding cognitive decline by years

— Spontaneous parkinsonism (bradykinesia, rigidity, postural instability; tremor less prominent than idiopathic PD)

— Older adult (typically >60) with new cognitive complaints plus visual hallucinations early in course

— Patient on antipsychotic for "agitation" who develops severe rigidity, confusion, or NMS-like reaction

— Long-standing RBD now developing executive dysfunction or visuospatial errors (clock drawing, intersecting pentagons)

— Recurrent unexplained falls in a patient with subtle parkinsonism

Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia after Alzheimer disease (AD), accounting for ~5–15% of dementia cases in tertiary memory clinics.

Pathology: intraneuronal α-synuclein aggregates (Lewy bodies) in cortex, limbic structures, and brainstem; overlaps biochemically with Parkinson disease dementia (PDD).

Core clinical tetrad to anchor suspicion:

Supportive features: severe neuroleptic sensitivity, autonomic dysfunction (orthostasis, constipation, urinary urgency), hyposmia, depression, repeated falls/syncope, transient unexplained loss of consciousness.

When to suspect on Step 3:

Key distinction: DLB vs PDD is operationalized by the "1-year rule" — if dementia begins before or within 1 year of motor parkinsonism, call it DLB; if motor symptoms precede dementia by >1 year, call it PDD. Both share α-synuclein biology and management overlaps heavily.

Board pearl: Early, prominent visuospatial and attentional/executive deficits with relatively preserved memory distinguish DLB from AD, where episodic memory loss dominates first.

Mean age of onset is 50s–80s; men slightly more affected; survival from diagnosis averages 5–8 years.

Presentation Patterns and Key History

— Spouse reports the patient "is sharp one hour, lost the next" — cognitive fluctuations lasting minutes to days

— Patient sees children, animals, or strangers in the home; initially with insight, later without

— Bed partner describes shouting, punching, or leaping out of bed during sleep (RBD) — often present for 5–15 years before cognition declines

— Subtle shuffling gait, stooped posture, reduced arm swing

— Syncope or near-syncope on standing; constipation; erectile dysfunction; urinary urgency (autonomic failure)

— Difficulty with attention (serial 7s, digit span backward)

— Visuospatial impairment — intersecting pentagons, clock drawing with planning errors

— Executive dysfunction — Trail Making B, verbal fluency

— Memory often retrievable with cues (vs AD where storage itself fails)

— Any prior reaction to antiemetics (prochlorperazine, metoclopramide) or antipsychotics producing severe rigidity, somnolence, or confusion strongly suggests DLB

— Anticholinergics (diphenhydramine, oxybutynin, TCAs) worsening cognition

Index visit clues that should redirect a "rule out Alzheimer" workup toward DLB:

Cognitive profile to elicit:

Functional history: driving errors (misjudging distance), getting lost in familiar places, mistaking objects for people (illusions/pareidolia), depression, apathy.

Drug-exposure history is critical:

Family/social history: RBD in first-degree relatives; occupational pesticide exposure (weak association); review caregiver burden.

CCS pearl: When the simulated case opens with "recurrent visual hallucinations" or "acting out dreams," order MoCA, orthostatics, medication reconciliation, TSH, B12, RPR, HIV, CMP, CBC as your initial screen — same dementia workup, but you've already narrowed the differential.

Board pearl: RBD is the single most specific prodromal marker — >80% of polysomnogram-confirmed RBD patients eventually develop a synucleinopathy (DLB, PD, or MSA).

Physical Exam Findings and Hemodynamic Assessment

— MoCA typically shows disproportionate loss on clock draw, cube copy, trails, attention; recall may improve with category cues

— Observe for drowsiness, staring spells, disorganized speech during the visit — manifestations of fluctuation

— Ask patient to describe hallucinations: fully formed, silent, often non-threatening people or animals

— Symmetric bradykinesia and rigidity (cogwheeling); tremor present in only ~50% and usually less prominent than idiopathic PD

— Postural instability early — positive pull test

— Hypomimia, hypophonia, micrographia, festinating gait

— Myoclonus may be seen (rare in PD; suggests DLB or CJD)

— Orthostatic vitals: drop ≥20 mmHg systolic or ≥10 mmHg diastolic within 3 minutes of standing without compensatory HR rise (neurogenic orthostatic hypotension)

— Supine hypertension often coexists — measure BP in both supine and standing positions

— Check anhidrosis, gastroparesis signs, bladder distention

Mental status exam:

Motor exam (parkinsonism):

Autonomic/hemodynamic assessment (essential in DLB):

Cardiovascular: rule out competing causes of syncope — carotid bruits, AS murmur, irregular rhythm; obtain ECG looking for QTc prolongation (relevant before any antipsychotic is considered).

Neuro-ophthalmologic: preserved vertical gaze (vs PSP where vertical gaze palsy dominates); pupils normal.

Key distinction: Symmetric parkinsonism + early postural instability + cognitive change points to DLB; asymmetric tremor-predominant parkinsonism with preserved cognition points to idiopathic PD.

Step 3 management: Document orthostatic vitals at every visit — orthostatic hypotension in DLB is a major driver of falls, hospitalization, and medication-limiting toxicity, and influences your choice of dopaminergic therapy and antihypertensive deprescribing.

Diagnostic Workup — Initial Labs, Imaging, and Biomarkers

— CBC, CMP, TSH, vitamin B12, folate

— RPR/treponemal test, HIV (reversible causes per AAN guideline)

— Consider methylmalonic acid if B12 borderline; homocysteine; HbA1c

— Urinalysis if fluctuating cognition (occult UTI is classic precipitant of acute worsening)

— Depression screen (PHQ-9) — pseudodementia mimic

— MRI brain (preferred) or non-contrast CT if MRI contraindicated

— DLB classically shows relative preservation of medial temporal lobes/hippocampi — contrasts with AD's hippocampal atrophy (a supportive indicative biomarker)

— Rule out NPH (ventriculomegaly with disproportionate sulcal effacement), subdural, tumor, infarcts

— Reduced dopamine transporter (DaT) uptake in basal ganglia on SPECT/PET

— PSG-confirmed REM sleep without atonia

— Low uptake on ¹²³I-MIBG myocardial scintigraphy (postganglionic sympathetic denervation)

DLB remains a clinical diagnosis anchored by the 2017 McKeith consortium criteria — labs and imaging are largely to exclude mimics and provide supportive biomarkers.

Initial dementia evaluation (order at first visit):

Structural neuroimaging:

ECG: baseline before any cholinesterase inhibitor (bradycardia/syncope risk) and before any antipsychotic (QTc).

Polysomnography if RBD is suspected — confirms REM sleep without atonia, an indicative biomarker under McKeith criteria.

Cognitive testing: MoCA preferred over MMSE because it captures executive and visuospatial deficits central to DLB.

Board pearl: Three "indicative biomarkers" that, with one core clinical feature, allow diagnosis of probable DLB:

Key distinction: A normal DaT scan effectively rules out DLB/PD spectrum and redirects you toward AD, vascular dementia, or frontotemporal dementia.

Step 3 management: Always screen for and treat delirium superimposed on dementia before attributing acute decline to disease progression.

Diagnostic Workup — Advanced and Confirmatory Studies

— Shows reduced striatal dopamine transporter binding (asymmetric "period" → "comma" → absent putaminal uptake)

— High sensitivity/specificity (~80%/90%) for distinguishing DLB from AD

— Cannot distinguish DLB from PD or PSP/MSA — those also show reduced DaT uptake

— Reduced heart-to-mediastinum ratio reflects cardiac sympathetic denervation

— Highly specific for Lewy body disease; helps separate DLB from AD and from atypical parkinsonisms (MSA preserves MIBG uptake early)

— AD profile (low Aβ42, high p-tau) argues for AD or mixed pathology

— α-synuclein seed amplification assay (SAA / RT-QuIC) is an emerging, highly sensitive/specific test for synucleinopathy and now appears in updated diagnostic frameworks

— Diagnostic uncertainty between DLB and AD when management hinges on the answer (e.g., avoiding antipsychotics, considering cholinesterase inhibitor)

— Atypical features raising concern for CJD (myoclonus, rapid decline → EEG, MRI DWI, CSF RT-QuIC for prion, 14-3-3)

— Suspected NPH → high-volume LP / CSF tap test

DaT-SPECT (¹²³I-ioflupane) — FDA-approved imaging adjunct:

¹²³I-MIBG cardiac scintigraphy:

FDG-PET: occipital hypometabolism with cingulate island sign (preserved posterior cingulate relative to precuneus) supports DLB over AD.

CSF biomarkers:

EEG: may show posterior slowing with prominent transient temporal slow-wave activity — supportive but nonspecific.

When to pursue advanced testing on Step 3:

Probable DLB (McKeith 2017): dementia plus ≥2 core features, OR 1 core feature + ≥1 indicative biomarker.

Possible DLB: 1 core feature alone, OR ≥1 indicative biomarker without core features.

Board pearl: Imaging cannot replace clinical criteria — a positive DaT scan in a cognitively normal patient does not diagnose DLB; it diagnoses a synucleinopathy spectrum disorder.

Key distinction: In suspected rapidly progressive dementia (<2 years), pursue CJD workup before settling on DLB.

Risk Stratification and First-Line Management Logic

— Cognitive/behavioral → cholinesterase inhibitor

— Psychotic symptoms (distressing hallucinations, delusions) → reduce offending meds first; pimavanserin or low-dose quetiapine/clozapine if needed

— Parkinsonism → low-dose carbidopa-levodopa

— RBD → melatonin first-line; clonazepam if refractory

— Orthostatic hypotension → non-pharm then midodrine/droxidopa/fludrocortisone

— Depression → SSRI/SNRI (avoid TCAs — anticholinergic burden)

— Constipation, urinary urgency, sialorrhea → targeted symptomatic care

— Stop or minimize anticholinergics (diphenhydramine, oxybutynin, TCAs, scopolamine) — cognition, hallucinations, constipation, falls all worsen

— Stop typical and most atypical antipsychotics — severe neuroleptic sensitivity reaction in ~30–50% (rigidity, confusion, autonomic instability, NMS-like, increased mortality)

— Avoid benzodiazepines, zolpidem, opioids, first-generation antihistamines

— Re-evaluate antihypertensives if orthostatic

— Caregiver education on fluctuations (these are not "faking")

— Fall prevention: home PT/OT, remove rugs, night lights, raised toilet seat

— Driving evaluation early — most DLB patients eventually unsafe

— Advance care planning while capacity is preserved

DLB has no disease-modifying therapy — management is symptom-targeted, multidomain, and longitudinal, with heavy attention to avoiding iatrogenesis.

Stratify by dominant symptom cluster at each visit and treat the most disabling domain first:

Universal first move at diagnosis: medication reconciliation and deprescribing:

Non-pharm foundation:

CCS pearl: On a simulated case, your first orders after diagnosis should be: medication reconciliation (discontinue anticholinergics/antipsychotics), home safety/PT referral, caregiver counseling, advance directives, and a cholinesterase inhibitor — not aggressive symptom-suppressing polypharmacy.

Key distinction: Aggressively treating one symptom (e.g., levodopa for stiffness) commonly worsens another (hallucinations) — think in tradeoffs, not silver bullets.

Pharmacotherapy — First-Line Drug Regimen

— Rivastigmine (FDA-approved for PDD; widely used in DLB) — oral 1.5 mg BID → titrate to 6 mg BID; transdermal patch 4.6 → 9.5 → 13.3 mg/24h (better tolerability)

— Donepezil — 5 mg → 10 mg daily; strong off-label evidence in DLB

— Benefits: improved attention, reduced visual hallucinations, modest cognitive gains — often more robust response than in AD

— Adverse effects: nausea, vomiting, diarrhea, weight loss, vivid dreams, bradycardia/syncope (check ECG; caution with beta-blockers, AV block), urinary urgency

— Start low (25/100 mg ½ tab TID) and titrate slowly to minimize hallucinations and orthostasis

— DLB patients respond less robustly than idiopathic PD; aim for functional improvement, not symptom eradication

— Avoid dopamine agonists (pramipexole, ropinirole), anticholinergics (trihexyphenidyl, benztropine), and amantadine when possible — high risk of psychosis and confusion

— Pimavanserin (5-HT2A inverse agonist) — preferred when available; no dopamine blockade; black-box warning for increased mortality in dementia-related psychosis (class effect for all antipsychotics)

— Quetiapine low-dose (12.5–50 mg) or clozapine (requires ANC monitoring) — only acceptable atypical alternatives

— Absolutely avoid haloperidol, risperidone, olanzapine — high D2 blockade → neuroleptic sensitivity

Cognitive symptoms — cholinesterase inhibitors (ChEIs) are first-line and evidence-supported:

Memantine — NMDA antagonist; modest benefit in moderate-severe DLB/PDD; add when ChEI plateaus.

Parkinsonism — carbidopa-levodopa:

Psychosis — if non-pharm strategies and cause reversal fail:

RBD: melatonin 3–12 mg at bedtime first-line (safer in elderly); clonazepam 0.25–0.5 mg second-line but worsens cognition/falls.

Depression/anxiety: sertraline, citalopram, escitalopram, venlafaxine; avoid TCAs and paroxetine (anticholinergic).

Board pearl: A trial of a cholinesterase inhibitor may simultaneously improve hallucinations and cognition in DLB — try this before reaching for any antipsychotic.

Expanded Pharmacology — Autonomic, Sleep, and Behavioral Symptoms

— Non-pharm first: increase salt (10 g/day) and fluids (2–2.5 L), compression stockings to waist, abdominal binder, head-of-bed elevation 30° (reduces supine HTN and nocturnal natriuresis), slow positional changes, avoid large carbohydrate meals/alcohol

— Review and taper antihypertensives, alpha-blockers, diuretics, nitrates, PDE5 inhibitors

— Midodrine 2.5–10 mg TID (avoid within 4h of bedtime — supine HTN)

— Droxidopa 100–600 mg TID (norepinephrine prodrug; FDA-approved for nOH)

— Fludrocortisone 0.1–0.2 mg daily (caution: hypokalemia, edema, supine HTN, CHF)

— Pyridostigmine as adjunct — minimal supine HTN, modest effect

— Identify triggers: pain (give scheduled acetaminophen), UTI, constipation, sensory deprivation, environmental change

— Behavioral interventions first

— If pharmacotherapy required: pimavanserin, quetiapine, or clozapine at lowest effective dose, time-limited, with documented risk-benefit discussion

Neurogenic orthostatic hypotension (nOH) — common, dangerous, and a leading cause of injurious falls:

Supine hypertension management: avoid pressors near bedtime; consider short-acting evening antihypertensive (losartan or hydralazine) if BP >160/100 supine.

Constipation: osmotic laxatives (polyethylene glycol), fiber, hydration; avoid anticholinergic antispasmodics.

Urinary urgency/incontinence: mirabegron preferred (β3 agonist, no anticholinergic burden); avoid oxybutynin/tolterodine; consider PVR check.

Sialorrhea: glycopyrrolate is anticholinergic but doesn't cross BBB — usable cautiously; botulinum toxin to salivary glands is alternative.

Sleep disturbance beyond RBD: sleep hygiene, treat OSA (CPAP); melatonin; avoid Z-drugs and benzodiazepines.

Agitation/behavioral disturbance:

Step 3 management: Every new symptomatic medication in DLB demands explicit reassessment of cognition, gait, hallucinations, and orthostatic vitals at 2–4 weeks — deprescribe if no clear benefit. Polypharmacy is the enemy.

Special Populations — Elderly and Renal/Hepatic Impairment

— Start at half the usual adult dose, titrate every 2–4 weeks

— Use Beers Criteria and STOPP/START as systematic deprescribing tools

— Reassess goals of care at every transition

— Donepezil — hepatic metabolism (CYP2D6/3A4); no renal dose adjustment; caution in moderate-severe hepatic impairment

— Rivastigmine — minimal hepatic metabolism (renally and esterase-cleared); dose-adjust by body weight (<50 kg → lower target); patch better tolerated in low-weight/frail elderly

— Both: monitor HR, weight, GI tolerability; check ECG if syncope, bradycardia, or AV block history

— Baseline falls, sarcopenia, and polypharmacy amplify all AEs

— Weight loss on ChEIs may necessitate switch from oral to patch or dose reduction

— Monitor for delirium at every acute illness or hospitalization

— Sundowning, restraints, urinary catheters, and PRN antipsychotics all worsen outcomes

— Ensure "avoid typical antipsychotics — Lewy body sensitivity" is prominent in the chart

Virtually all DLB patients are elderly, so geriatric pharmacology principles apply universally:

Cholinesterase inhibitors:

Carbidopa-levodopa: dose-related orthostasis and hallucinations; renal clearance — reduce dose in CKD if confusion or somnolence develops.

Memantine: renally cleared — reduce to 5 mg BID if CrCl 5–29 mL/min; standard dosing otherwise.

Midodrine: active metabolite renally cleared — reduce dose in CKD; contraindicated in severe organic heart disease, urinary retention, pheochromocytoma, thyrotoxicosis.

Droxidopa: dose-adjust in renal impairment; monitor supine BP.

Hepatic impairment: prefer rivastigmine over donepezil; reduce SSRIs (sertraline, citalopram) by 50%; avoid TCAs.

Frailty considerations:

Hospitalization risks:

Board pearl: Acute decline in a DLB patient is delirium until proven otherwise — check UA, CBC, BMP, medication list, oxygenation, and pain before increasing dementia-directed therapy.

Step 3 management: Use deprescribing visits every 6 months — review every drug against current symptoms, anticholinergic burden score, and goals of care.

Special Populations — Younger-Onset, Caregivers, and Genetic Considerations

— Less common but well-described; tends to present with more prominent psychiatric features (depression, anxiety, psychosis) that may be misdiagnosed as primary psychiatric illness — and treated with antipsychotics, precipitating crisis

— Genetic contribution larger: consider GBA mutations (glucocerebrosidase — also Gaucher carrier), SNCA duplications/triplications, APOE ε4 as risk modifier

— Refer to genetic counseling when family history is striking or onset <60

— Spouses are often elderly with their own comorbidities

— Adult-child caregivers face employment and childcare conflicts

— Screen caregivers for depression, burnout, sleep deprivation at every visit (Zarit Burden Interview)

— Connect to Lewy Body Dementia Association, local Area Agency on Aging, adult day programs, respite care

— Palliative care referral early — not just end-of-life; helps with symptom prioritization and advance planning

— Discuss hospice eligibility when FAST stage 7, recurrent infections, weight loss, or aspiration develop

— Black and Hispanic patients are underdiagnosed with DLB; consider DLB in any older adult with hallucinations or fluctuations regardless of demographic assumptions

— Address health literacy and translated educational materials

Younger-onset DLB (<65 years):

Pregnancy/pediatrics: DLB does not occur in pregnancy or children — focus instead on caregiver demographics:

Caregiver-focused interventions (Step 3 emphasis on longitudinal/system care):

Underserved populations:

Veterans: higher RBD prevalence in TBI history; check VA benefits eligibility.

LGBTQ+ caregivers: ensure surrogate decision-maker documentation is legally robust (durable POA for healthcare) given variable state recognition.

Key distinction: Frontotemporal dementia is the more typical younger-onset dementia — but if hallucinations, RBD, or parkinsonism are present, pivot toward DLB even in 50s.

Board pearl: GBA mutation carriers have an ~5–10× increased risk of DLB/PD — relevant when family history includes both Parkinson disease and Gaucher disease.

Step 3 management: Build the caregiver into the treatment plan at every visit — they are the eyes, ears, and medication safety system.

Complications and Adverse Outcomes

— Driven by parkinsonism, orthostasis, fluctuating attention, RBD-related nocturnal injuries, and medication adverse effects

— Hip fracture in a DLB patient carries higher mortality than in AD due to perioperative delirium and immobility

— Occurs in 30–50% with typical or high-D2-affinity atypical antipsychotics

— Presents as acute worsening of parkinsonism, confusion, somnolence, autonomic instability, and NMS-like syndrome

— Mortality risk 2–3× baseline — among the most important iatrogenic complications in medicine

— Frequently triggered by UTI, dehydration, surgery, new medications, opioid use

— Often prolonged and incompletely reversible

— Syncope, supine hypertension, urinary retention, severe constipation/ileus, gastroparesis

Falls and fall-related injury — leading cause of ED visits and hospitalization:

Neuroleptic sensitivity reaction:

Aspiration pneumonia: dysphagia from parkinsonism and impaired cough; recurrent admissions in late-stage disease; a hospice-qualifying event.

Delirium superimposed on dementia:

Autonomic complications:

Behavioral and psychiatric crises: Capgras syndrome (familiar person is an impostor), delusions of infidelity, severe agitation requiring ED visit — high risk of inappropriate antipsychotic exposure in unfamiliar settings.

Weight loss and malnutrition: ChEI-induced GI effects, depression, dysphagia, loss of olfaction.

Pressure injuries and immobility complications in late disease.

Driving accidents: visuospatial deficits + fluctuations + parkinsonism = high risk; assess and counsel proactively.

Caregiver morbidity: depression, cardiovascular disease, premature mortality.

Suicide risk: elevated in early DLB with preserved insight, depression, and grief about diagnosis — screen explicitly.

CCS pearl: When the simulated case mentions a DLB patient on haloperidol or risperidone, your immediate orders are: stop the offending agent, IV fluids, supportive care, monitor temperature/CK/autonomic vitals, and substitute pimavanserin or low-dose quetiapine if absolutely needed.

Board pearl: Median survival from DLB diagnosis is 5–8 years, shorter than AD, largely due to falls, aspiration, and antipsychotic exposure.

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Suspected neuroleptic sensitivity reaction or NMS (rigidity, hyperthermia, autonomic instability, elevated CK) — admit, often ICU

— Acute delirium unresponsive to outpatient management or with unsafe behavior

— Syncope or fall with head injury, fracture, or new neuro deficit

— Aspiration pneumonia with hypoxia or sepsis

— Severe dysphagia with weight loss or recurrent infection

— Neurology / behavioral neurology / movement disorders — diagnostic uncertainty, refractory motor or psychiatric symptoms, consideration of advanced biomarkers

— Sleep medicine — confirmatory PSG, RBD management, comorbid OSA

— Psychiatry / geriatric psychiatry — severe agitation, depression with suicidality, family conflict around capacity

— Cardiology — syncope workup, ECG abnormalities before ChEI initiation, refractory orthostatic hypotension

— Palliative care — symptom burden, goals of care, advance planning (early, not late)

— PT/OT, speech-language pathology — gait training, swallow evaluation, communication strategies

— Social work and case management — caregiver support, home services, long-term care planning

— Order set: flag DLB and "avoid typical antipsychotics" prominently; allow melatonin, low-dose quetiapine PRN, scheduled acetaminophen for pain

— Continue home cholinesterase inhibitor and carbidopa-levodopa on schedule — abruptly stopping levodopa risks neuroleptic-malignant-like syndrome

— Minimize lines, catheters, restraints; mobilize early; family at bedside

— Daily delirium screen (CAM)

— Discharge planning from day 1 — home, SNF, or hospice

Emergency department / urgent referral indications:

Specialty consultations:

Hospital management principles (CCS-style):

ICU admission triggers: autonomic crisis with hemodynamic instability, severe NMS-like reaction, status epilepticus (rare), severe aspiration with respiratory failure (after goals-of-care discussion).

CCS pearl: On a CCS DLB case, never order haloperidol PRN for agitation — failure to deprescribe or wrong-drug orders are scored heavily against you. Choose quetiapine 12.5–25 mg PRN or treat the underlying delirium driver.

Step 3 management: Use every hospitalization as an opportunity for goals-of-care conversation and medication reconciliation.

Key Differentials — Other Dementias and Synucleinopathies

— Memory-predominant decline with early hippocampal atrophy on MRI

— Hallucinations and parkinsonism are late features, not early

— CSF: low Aβ42, high p-tau; amyloid PET positive

— Distinguishing test: DaT scan normal in AD, reduced in DLB

— Same α-synuclein biology as DLB; differs only in timing — dementia >1 year after motor symptoms

— Management nearly identical; rivastigmine FDA-approved

— "1-year rule" is arbitrary but board-tested

— α-synucleinopathy with prominent early autonomic failure, cerebellar ataxia (MSA-C), or parkinsonism (MSA-P)

— Cognition relatively preserved until late — key distinction from DLB

— MIBG cardiac uptake preserved (vs reduced in DLB/PD)

— Hot cross bun sign on pontine MRI (MSA-C)

— Tauopathy with vertical supranuclear gaze palsy, early falls (backward), axial rigidity, frontal-executive dysfunction, pseudobulbar affect

— No prominent visual hallucinations or fluctuations

— MRI: hummingbird/penguin sign (midbrain atrophy)

— Asymmetric rigidity/apraxia, alien limb phenomenon, cortical sensory loss

— Less prominent hallucinations and fluctuations

— Younger onset; behavioral disinhibition or aphasia predominate; visuospatial relatively spared

— Lacks hallucinations and parkinsonism

— Stepwise decline; focal neuro deficits; strategic infarcts on MRI; vascular risk factor profile

— May coexist with DLB (mixed dementia is common)

Alzheimer disease (AD):

Parkinson disease dementia (PDD):

Multiple system atrophy (MSA):

Progressive supranuclear palsy (PSP):

Corticobasal degeneration (CBD):

Frontotemporal dementia (FTD):

Vascular dementia:

Board pearl: Visual hallucinations early + RBD + parkinsonism + fluctuations + cognitive change = DLB, regardless of which symptom appeared first; PDD only if motor symptoms predated cognition by >1 year.

Key distinction: Autonomic failure with preserved cognition = MSA; with prominent cognition/hallucinations = DLB.

Key Differentials — Non-Degenerative and Reversible Mimics

— Acute onset, fluctuating, inattention — overlaps heavily with DLB fluctuations

— Look for precipitant: infection (UTI most common in elderly), metabolic derangement, drug effect, hypoxia

— Resolves with treatment of underlying cause — DLB fluctuations do not

— Anticholinergics → confusion, hallucinations (mimic DLB)

— Dopamine blockers (metoclopramide, prochlorperazine, antipsychotics) → drug-induced parkinsonism

— Lithium toxicity, valproate → tremor, cognitive slowing

— Opioids, benzodiazepines → confusion, falls

— Resolution after withdrawal distinguishes from DLB

— Wet, wacky, wobbly — urinary incontinence, cognitive slowing, magnetic gait

— MRI: ventriculomegaly disproportionate to sulcal atrophy, Evans index >0.3

— Diagnostic tap test / external lumbar drain → gait improvement

— Treat with VP shunt; potentially reversible

— Rapidly progressive (<1 year) dementia with myoclonus, ataxia, visual symptoms

— MRI DWI: cortical ribbon and basal ganglia hyperintensities

— EEG: periodic sharp wave complexes

— CSF: 14-3-3, RT-QuIC positive

— LGI1, CASPR2, NMDAR, anti-Hu, anti-Ma antibodies

— Subacute onset, seizures, faciobrachial dystonic seizures (LGI1), psychiatric features

— Treatable with immunotherapy — don't miss

— Triad: confusion, ataxia, ophthalmoplegia; alcohol use disorder or malnutrition

— Treat with IV thiamine before glucose

Delirium:

Medication-induced cognitive/motor syndromes:

Normal pressure hydrocephalus (NPH):

Creutzfeldt-Jakob disease (CJD):

Autoimmune/limbic encephalitis:

Wernicke encephalopathy:

Hypothyroidism, B12 deficiency, neurosyphilis, HIV-associated cognitive disorder: the reversible dementia panel — always check.

Depression (pseudodementia): preserved attention, "I don't know" answers, improves with antidepressant.

OSA: untreated sleep apnea → daytime cognitive impairment; treat with CPAP.

Key distinction: Sudden onset or rapid (<6 months) decline should redirect workup toward delirium, autoimmune encephalitis, CJD, or vascular cause — DLB progression is gradual.

Board pearl: Always rule out reversible mimics before settling on DLB — the diagnosis carries irreversible therapeutic and prognostic implications.

Long-Term Plan, Secondary Prevention, and Disease-Spectrum Care

— Cholinesterase inhibitor (donepezil or rivastigmine) — continue as long as benefit outweighs side effects; consider deprescribing in late-stage disease when cognitive benefit unclear

— Carbidopa-levodopa at lowest effective dose

— Melatonin for RBD

— Midodrine/droxidopa/fludrocortisone for nOH as needed

— SSRI for depression if indicated

— Pimavanserin or low-dose quetiapine for refractory psychosis (with documented informed consent given black-box warning)

— BP control aiming for modest targets (e.g., SBP 130–140) to balance perfusion and orthostasis

— Statin per ASCVD risk; antiplatelet only for established indications

— Glycemic control (HbA1c target 7.0–7.5% in older adults; relax to 8.0% in advanced dementia per ADA)

— Smoking cessation, moderate physical activity (tai chi, supervised walking)

— POLST/MOLST forms; designated healthcare surrogate

— Code status discussions revisited with disease progression

— Discuss feeding tubes (generally not recommended in advanced dementia per AGS), hospitalization preferences, hospice

No disease-modifying therapy exists — the "long-term plan" is symptom optimization, prevention of iatrogenic harm, and proactive transitions of care.

Core long-term medication list to maintain and titrate:

Vascular risk factor management — coexisting cerebrovascular disease accelerates decline:

Vaccinations: annual influenza, COVID-19, RSV, pneumococcal (PCV20 or PCV15+PPSV23), Tdap, zoster — reduce infection-triggered delirium.

Nutrition and bone health: vitamin D, calcium, fall risk → consider bone density and osteoporosis treatment.

Drug-list pruning at every visit: anticholinergic burden score, Beers criteria — major secondary prevention lever.

Advance care planning (longitudinal, not one-time):

Caregiver support and respite as a prescribed, recurring intervention.

Step 3 management: At each visit, ask: What can I stop? What is the goal? Is the caregiver okay? — three questions that drive value-based dementia care.

Board pearl: Cholinesterase inhibitors and avoidance of antipsychotics are the two highest-yield therapeutic interventions in DLB.

Follow-Up, Monitoring Parameters, and Counseling

— Initial diagnosis and titration phase: every 4–8 weeks until medications stable

— Stable maintenance: every 3–6 months

— More frequent at transitions of care (post-hospitalization, caregiver change, new symptoms)

— Cognition: MoCA annually; functional status (IADLs, ADLs) every visit

— Motor: UPDRS or simple bedside assessment (gait, rigidity, bradykinesia, falls since last visit)

— Behavioral/psychiatric: Neuropsychiatric Inventory (NPI) brief — hallucinations, delusions, depression, anxiety, agitation

— Sleep: RBD episodes, daytime sleepiness, OSA symptoms

— Autonomic: orthostatic vitals, constipation, urinary symptoms, sexual function

— Caregiver: burden score (Zarit), depression (PHQ-9), respite needs

— Safety: falls, driving, firearm access, medication adherence and storage

— ChEI: weight, pulse, GI tolerance; ECG if syncope

— Carbidopa-levodopa: hallucinations, orthostasis, dyskinesias

— Pimavanserin/quetiapine: QTc, sedation, mortality risk re-discussion

— Midodrine: supine HTN at bedtime

— Fludrocortisone: K⁺, edema, BP

— Fluctuations are biological, not behavioral

— Hallucinations may not require treatment if non-distressing and patient retains insight

— Driving cessation — assess with on-road test; involve DMV per state mandatory reporting laws

— Firearm safety — strongly advise removal from home

— Financial and legal capacity — encourage early power of attorney

— PT — gait, balance, tai chi, LSVT-BIG protocol

— OT — home safety, adaptive equipment, energy conservation

— SLP — LSVT-LOUD for hypophonia; swallow evaluation for dysphagia

— Cognitive rehabilitation, structured day programs

Follow-up cadence:

At each visit, assess:

Drug-specific monitoring:

Counseling priorities:

Rehabilitation referrals:

CCS pearl: Schedule the next visit before the patient leaves — DLB patients lost to follow-up commonly return via the ED in crisis.

Board pearl: Annual driving evaluation is standard of care; document the conversation.

Ethical, Legal, and Patient Safety Considerations

— Capacity is decision-specific and time-specific — fluctuates within a day in DLB

— Assess during a lucid interval when possible; document the specific decision and patient's reasoning

— Use surrogate decision-maker (durable POA for healthcare → spouse/next-of-kin hierarchy by state law) when capacity is lacking

— Antipsychotic prescribing carries a black-box warning for increased mortality in dementia-related psychosis — informed consent (patient and/or surrogate) must be documented, including the specific Lewy-body neuroleptic sensitivity risk

— Cholinesterase inhibitors near end-stage disease — discuss goals before continuing

— Research participation — additional surrogate consent and assent processes

— Impaired drivers — many states (CA, OR, PA, others) require physician reporting of dementia diagnosis to DMV; know your state law

— Elder abuse, neglect, or financial exploitation — mandatory reporting to Adult Protective Services in all 50 states

— Self-neglect (patient living alone with unsafe behaviors) often qualifies

— Initiate early while capacity is preserved

— Address feeding tubes (generally not beneficial in advanced dementia — AGS Choosing Wisely), CPR, hospitalization preferences, hospice

— POLST/MOLST forms portable across care settings

— Hospital → home/SNF transitions are high-risk for medication errors and delirium

— Ensure explicit "avoid typical antipsychotics — Lewy body sensitivity" alert in the chart and discharge summary

— Medication reconciliation by pharmacist; teach-back with caregiver

— Follow-up call within 48–72 hours; clinic visit within 1–2 weeks

Decision-making capacity:

Informed consent edge cases:

Mandatory reporting (state-dependent):

Driving and firearms: counsel and document; involve family; pursue legal cessation if patient lacks insight and continues to drive unsafely.

Advance care planning:

Transitions-of-care safety (Step 3 priority):

Research and end-of-life: brain donation may be offered for definitive pathologic diagnosis and research; address with sensitivity.

Board pearl: A suicide risk discussion is mandatory in early-stage DLB — preserved insight + grief about diagnosis + depression = high-risk profile.

Step 3 management: Document capacity assessments, mandatory reports, and antipsychotic informed consent — these are tested vignette elements.

High-Yield Associations and Rapid-Fire Clinical Facts

Pathology: α-synuclein-positive Lewy bodies and Lewy neurites in cortex, limbic system, brainstem; frequent co-pathology with AD changes (amyloid plaques, tau tangles) — "mixed" pathology is the rule.

Genetics: GBA mutations (highest single-gene risk), SNCA, APOE ε4 modifier.

The "1-year rule": dementia ≤1 year of parkinsonism → DLB; >1 year after → PDD.

McKeith core features (2017): fluctuating cognition, recurrent visual hallucinations, RBD, spontaneous parkinsonism.

McKeith indicative biomarkers: reduced DaT uptake, RBD on PSG, reduced MIBG cardiac uptake.

MRI signature: relative sparing of hippocampi (vs AD).

FDG-PET: cingulate island sign + occipital hypometabolism.

EEG: posterior slowing.

Cognitive profile: attention/executive/visuospatial >> memory early on.

Pareidolia: seeing faces in random patterns — bedside clue.

Neuroleptic sensitivity: 30–50%; avoid haloperidol, risperidone, olanzapine; safest options are pimavanserin, clozapine, quetiapine.

First-line cognitive therapy: rivastigmine or donepezil — robust response often surpasses AD response.

First-line motor therapy: carbidopa-levodopa low and slow; avoid dopamine agonists and anticholinergics.

First-line RBD therapy: melatonin (safer than clonazepam in elderly).

First-line nOH therapy: non-pharm → midodrine → droxidopa → fludrocortisone.

Survival: 5–8 years from diagnosis.

Hospice qualifying events: FAST 7, recurrent aspiration, weight loss, stage 3+ pressure injury, recurrent UTI/sepsis.

Most underdiagnosed core feature: RBD — ask every patient and bed partner.

Most dangerous prescription: first-generation antipsychotic in undiagnosed DLB presenting as "agitation."

Most reversible cause of acute decline: UTI-triggered delirium.

Caregiver intervention with strongest evidence: structured multicomponent caregiver education + respite.

Anticholinergic culprits to memorize: diphenhydramine, oxybutynin, tolterodine, hyoscyamine, scopolamine, TCAs, benztropine, trihexyphenidyl, paroxetine, hydroxyzine.

Board pearl: When a Step 3 vignette includes "older patient with hallucinations who had a severe reaction to haloperidol" — the answer is DLB until proven otherwise.

Board Question Stem Patterns

— 72-year-old with 1-year cognitive decline, visual hallucinations of children, shuffling gait, and spouse reporting violent dream enactment for years

— Question: Most likely diagnosis? Answer: DLB

— Distractor: AD (no early hallucinations/RBD), PDD (motor first by >1 year)

— Patient with dementia given haloperidol in ED for agitation, now rigid, febrile, encephalopathic

— Question: Most likely underlying dementia? Answer: DLB

— Next step: stop antipsychotic, supportive care, consider bromocriptine/dantrolene if NMS criteria

— Newly diagnosed DLB with hallucinations and cognitive impairment

— Answer: Rivastigmine or donepezil — not antipsychotic

— Distressing refractory hallucinations despite ChEI

— Answer: Pimavanserin (best, no D2 blockade) or low-dose quetiapine/clozapine

— Wrong: haloperidol, risperidone, olanzapine

— Patient acting out dreams, injuring spouse

— Answer: Melatonin first; clonazepam second-line

— DLB patient with syncope on standing

— Steps: stop offending meds → salt/fluids/compression → midodrine or droxidopa

— Patient with parkinsonism + autonomic failure + preserved cognition + cerebellar signs

— Answer: MSA, not DLB

— Reduced striatal DaT uptake + preserved hippocampi → DLB, not AD

— Family asks about continuing donepezil in FAST-7 patient with recurrent aspiration

— Answer: Discuss goals of care; consider deprescribing and hospice

— Newly diagnosed DLB patient continues driving despite family concern; state law requires DMV notification

— Answer: Counsel cessation, document, and report per state statute

Stem 1 — Classic DLB presentation:

Stem 2 — Neuroleptic sensitivity:

Stem 3 — Best initial pharmacotherapy:

Stem 4 — Antipsychotic choice when truly needed:

Stem 5 — RBD management:

Stem 6 — Orthostatic hypotension:

Stem 7 — Differentiation:

Stem 8 — Imaging clue:

Stem 9 — Ethics/safety:

Stem 10 — Mandatory reporting:

Step 3 management: Recognize that questions test what NOT to give (haloperidol, diphenhydramine, oxybutynin) as often as what to give.

Board pearl: When a stem mentions "vivid dream enactment for years before cognitive symptoms," RBD is the prodromal flag — synucleinopathy spectrum is the answer.

One-Line Recap

Dementia with Lewy bodies is an α-synucleinopathy diagnosed clinically by fluctuating cognition, recurrent visual hallucinations, REM sleep behavior disorder, and spontaneous parkinsonism — managed by cholinesterase inhibitors, low-dose carbidopa-levodopa, melatonin for RBD, aggressive avoidance of typical antipsychotics and anticholinergics, and proactive caregiver, autonomic, and advance-care-planning support.

Diagnose with the McKeith 2017 criteria — probable DLB = dementia + ≥2 core features OR 1 core feature + ≥1 indicative biomarker (DaT-SPECT, PSG-confirmed RBD, reduced MIBG cardiac uptake); MRI typically spares hippocampi; FDG-PET shows the cingulate island sign and occipital hypometabolism.

Treat cognition and hallucinations first with a cholinesterase inhibitor (rivastigmine or donepezil) before any antipsychotic; if antipsychotic is truly required for distressing psychosis, choose pimavanserin, clozapine, or low-dose quetiapine — never haloperidol, risperidone, or olanzapine (severe neuroleptic sensitivity, 2–3× mortality).

Manage parkinsonism with low-dose carbidopa-levodopa, RBD with melatonin, neurogenic orthostatic hypotension with non-pharm measures plus midodrine, droxidopa, or fludrocortisone, and continuously deprescribe anticholinergics, benzodiazepines, and dopamine blockers.

Build longitudinal care: every visit includes orthostatic vitals, caregiver assessment, fall and driving safety, advance care planning, and a "what can I stop?" deprescribing pass — because in DLB, what you withhold matters as much as what you prescribe.

Step 3 management: Flag "Lewy body — avoid typical antipsychotics" in every chart and discharge summary, schedule follow-up within 1–2 weeks of any hospitalization, and integrate palliative care early to align symptom-directed therapy with patient and family goals across the 5–8-year disease trajectory.